Payment overview · 2025
General Payments
$53.62
3 reported records · 3 companies
Healthcare provider profile · identity verified
Laura E Alexander, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MERIDIAN, MS · NPI 1780881128
Verified facts
What the public records show
CMS Open Payments records show Laura E Alexander, D.O. received $53.62 in general payments during 2025 across 3 reported records.
Exact Sciences Corporation accounted for 35.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.98 | 35.4% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $18.15 | 33.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.49 | 30.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $53.62 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 137 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
137 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 441 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 398 | 95 |
| Potassium Chloride | Potassium Chloride | 391 | 96 |
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 90 |
| Gabapentin | Gabapentin | 367 | 77 |
| Famotidine | Famotidine | 345 | 88 |
| Furosemide | Furosemide | 327 | 82 |
| Sertraline Hcl | Sertraline Hcl | 299 | 52 |
| Clonidine Hcl | Clonidine Hcl | 261 | 56 |
| Azithromycin | Azithromycin | 259 | 121 |
| Linzess | Linaclotide | 255 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 62 |
| Lisinopril | Lisinopril | 237 | 58 |
| Prednisone | Prednisone | 221 | 78 |
| Eliquis | Apixaban | 220 | 33 |
| Glimepiride | Glimepiride | 220 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 47 |
| Farxiga | Dapagliflozin Propanediol | 214 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 212 | 48 |
| Omeprazole | Omeprazole | 209 | 58 |
| Buspirone Hcl | Buspirone Hcl | 190 | 40 |
| Fenofibrate | Fenofibrate | 189 | 53 |
| Jardiance | Empagliflozin | 187 | 33 |
| Nifedipine Er | Nifedipine | 173 | 40 |
| Doxazosin Mesylate | Doxazosin Mesylate | 171 | 38 |
| Pregabalin | Pregabalin | 165 | 36 |
| Tramadol Hcl | Tramadol Hcl | 165 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 32 |
| Carvedilol | Carvedilol | 152 | 46 |
| Allopurinol | Allopurinol | 145 | 35 |
| Methylprednisolone | Methylprednisolone | 142 | 113 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 141 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 39 |
| Levetiracetam | Levetiracetam | 138 | 21 |
| Montelukast Sodium | Montelukast Sodium | 138 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 138 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 137 | 22 |
| Metformin Hcl | Metformin Hcl | 131 | 36 |
| Simvastatin | Simvastatin | 125 | 33 |
| Meloxicam | Meloxicam | 122 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 20 |
| Losartan Potassium | Losartan Potassium | 119 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 48 |
| Cilostazol | Cilostazol | 100 | 18 |
| Memantine Hcl | Memantine Hcl | 98 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 24 |
| Meclizine Hcl | Meclizine Hcl | 93 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 40 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 81 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 80 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 52 |
| Tresiba Flextouch U-100 | Insulin Degludec | 77 | 17 |
| Ozempic | Semaglutide | 71 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 23 |
| Xarelto | Rivaroxaban | 66 | 12 |
| Ezetimibe | Ezetimibe | 64 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 17 |
| Novolin R | Insulin Regular, Human | 64 | 11 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Estradiol | Estradiol | 61 | 13 |
| Topiramate | Topiramate | 61 | suppressed |
| Gemfibrozil | Gemfibrozil | 60 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 13 |
| Propranolol Hcl | Propranolol Hcl | 60 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 47 |
| Trazodone Hcl | Trazodone Hcl | 58 | 15 |
| Cefuroxime | Cefuroxime Axetil | 57 | 39 |
| Nystatin | Nystatin | 57 | 34 |
| Januvia | Sitagliptin Phosphate | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 55 | 21 |
| Donepezil Hcl | Donepezil Hcl | 54 | 18 |
| Latanoprost | Latanoprost | 51 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 11 |
| Spironolactone | Spironolactone | 49 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 11 |
| Risperidone | Risperidone | 42 | suppressed |
| Valsartan | Valsartan | 42 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Glipizide | Glipizide | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 20 |
| Baclofen | Baclofen | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 36 | 18 |
| Metoclopramide Hcl | Metoclopramide Hcl | 36 | 11 |
| Temazepam | Temazepam | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 35 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 13 |
| Finasteride | Finasteride | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Humulin R | Insulin Regular, Human | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Lactulose | Lactulose | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | 13 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 27 | 16 |
| Lidocaine Hcl | Lidocaine Hcl | 27 | 16 |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 16 |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 15 |
| Levemir | Insulin Detemir | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Novolog | Insulin Aspart | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Xifaxan | Rifaximin | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.62 · 3 records | Exact Sciences Corporation | ACCRUFER, AREXVY, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error